|
End-of-day quote
London S.E.
|
||
| - GBX | - |
|
| 08-19 | GSK plc : Deutsche Bank remains Neutral | ZD |
| 08-17 | Chugai grants GSK exclusive global license for AID351 dengue antibody | AN |
| Market Cap | 76.77B 104B 89.4B 83.23B 144B 10,000B 147B 985B 386B 5,007B 392B 384B 16,514B | P/E 2026 * |
14.5x | P/E 2027 * | 11.9x |
|---|---|---|---|---|---|
| Enterprise Value | 95.97B 131B 112B 104B 180B 12,501B 183B 1,232B 482B 6,259B 490B 480B 20,644B | EV / Sales 2026 * |
2.83x | EV / Sales 2027 * | 2.62x |
| Free-Float |
92.75% | Yield 2026 * |
3.63% | Yield 2027 * | 3.91% |
Last Transcript: GlaxoSmithKline plc
| Manager | Title | Age | Since |
|---|---|---|---|
Luke Miels
CEO | Chief Executive Officer | - | 2025-12-31 |
Julie Brown
DFI | Director of Finance/CFO | 64 | 2023-04-30 |
| Chief Tech/Sci/R&D Officer | - | 2021-11-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Luke Miels
BRD | Director/Board Member | - | 2026-05-05 |
Hal Barron
BRD | Director/Board Member | 64 | 2017-12-31 |
Jonathan Symonds
CHM | Chairman | 68 | 2019-08-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +4.46% | +5.38% | +83.42% | +134.31% | 1,093B | |
| +0.85% | +5.24% | +55.13% | +58.51% | 653B | |
| +2.72% | +6.35% | +28.76% | +77.15% | 458B | |
| +1.80% | -0.41% | +43.52% | +44.05% | 355B | |
| +1.24% | +1.00% | +26.84% | +42.21% | 294B | |
| +2.07% | +1.74% | +2.66% | +13.06% | 248B | |
| +4.02% | +6.77% | +51.17% | +68.96% | 230B | |
| +1.05% | -2.52% | -13.83% | -52.13% | 203B | |
| +2.90% | +8.71% | +25.10% | +94.52% | 178B | |
| Average | +2.35% | +1.20% | +33.64% | +53.40% | 412.27B | |
| Weighted average by Cap. | +2.65% | +1.45% | +47.89% | +73.74% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 33.94B 46.16B 39.53B 36.8B 63.74B 4,421B 64.78B 436B 171B 2,213B 173B 170B 7,301B | 35.54B 48.34B 41.39B 38.53B 66.74B 4,629B 67.83B 456B 179B 2,318B 181B 178B 7,644B |
| Net income | 5.44B 7.39B 6.33B 5.89B 10.21B 708B 10.37B 69.76B 27.32B 354B 27.74B 27.16B 1,169B | 6.48B 8.82B 7.55B 7.03B 12.18B 845B 12.38B 83.22B 32.59B 423B 33.1B 32.4B 1,395B |
| Net Debt | 19.2B 26.11B 22.36B 20.82B 36.06B 2,501B 36.65B 246B 96.49B 1,252B 98B 95.94B 4,130B | 16.37B 22.27B 19.07B 17.75B 30.75B 2,133B 31.25B 210B 82.29B 1,068B 83.57B 81.81B 3,522B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
